Kornimate/medical-research-clean huggingface dataset:
comparison of resilience between adhd and controls.

Conditions: ADHD; Resilience; Stress

Summary: to explore if resilience serves as a mediator between adverse life events and emotional and behavioral problems, and compare the difference of resilience and its mediating effects between children and adolescents with and without adhd.


Eligibility criteria:
inclusion criteria: * adhd; control without adhd exclusion criteria: * asd, other major physical and psychiatric diseases
keep it up! 2.0: a comparison of two online hiv intervention programs for young men who have sex with men

Conditions: HIV; Gonorrhea; Chlamydia

Summary: young men who have sex with men (ymsm) account for almost 70% of hiv diagnoses among all young people in the u.s. and are alone in facing an increasing rate of infections. because ymsm are less likely to receive relevant sexual health education in traditional settings (e.g. schools, community), the internet is a unique route of reaching and helping ymsm. the purpose of this study is to compare two different versions of an online hiv prevention program for ymsm. the study is being conducted by researchers at northwestern university in chicago, hunter college in new york city, and emory university in atlanta. a total of 900 ymsm will be enrolled into this study from the clinics of community partners in chicago, new york, and atlanta. participants will be randomly assigned to one of two versions of the program. some topics in the program include hiv facts and myths, sexually transmitted infections (stis), and condom use. all participants, regardless of the program version they receive, will also take at-home urine and rectal tests for the stis chlamydia and gonorrhea. after completing the program, participants will be contacted three more times over the course of a year for follow-up sessions and surveys. the research team hypothesizes that the ymsm-specific prevention program will lead to a significant reduction in the frequency of unprotected anal sex acts and new sti infections compared to the hiv knowledge program that is for a general audience. the ymsm-specific program will also lead to improvements in secondary knowledge, motivation, and skills outcomes. in order for the research team to measure the effectiveness of the ymsm-specific prevention program and determine if the study hypothesis is correct, participants will be asked questions about themselves, including questions about their sexual orientation, sexual experiences, health practices, including drug use, health knowledge, and questions about their feelings and emotions. based on this information, the research team hopes to later change, improve, or expand the program to better address the needs of ymsm.


Eligibility criteria:
inclusion criteria: * birth male who identifies as male and reports sexual contact with another male * received an hiv negative test result from a participating clinic/recruitment site * unprotected anal sex with another male in the last 6 months * ability to read english at 8th grade level exclusion criteria: * hiv positive * female or transgender * no email address for contact * currently in a monogamous relationship lasting longer than 6 months * participated in previous versions of kiu!
effectiveness of microcurrents therapy in overactive bladder.

Conditions: Overactive Bladder; Urinary Incontinence

Summary: the purpose of this study is to investigate the effect on the overactive bladder in women using a care protocol plus the application of microcurrent patches during 1 hours per session compared to the effect of the same protocol plus placebo electric stimulation.

the design of this study is a multicentric, parallel, randomised, triple blind clinical trial with placebo control. the size of the sample will be 56 participants who come to referral hospitals. they will be randomized in two groups: control or experimental. the variables of the study will be collected at three time points: before the intervention, during the intervention and at the end of the intervention. the statistical analysis will be an intention-to-treat analysis. for the main outcomes variables a two factor anova will-be performed (intervention-time) with a post-hoc analysis with kruskal wallis correction correction. statistical significance will be defined as p \<0.05

Eligibility criteria:
inclusion criteria: * women, over 18 years of age and with urinary incontinence (3 or more times per week) or overactive bladder (8 or more emptied per day, and / or 2 or more at night) who have received, or not, active / alternative treatment for this pathology. * under competent cognitive conditions to participate in the study and trained to complete the study questionnaires. * without contraindications for a treatment with microcurrents: pacemakers, pregnant women, internal bleeding, do not apply electrodes on skin in poor condition, with ulcerations or wounds, acute febrile processes, acute thrombophlebitis and / or electricity phobia. exclusion criteria: * people with lifestyle habits (diet, amount of fluid ingested) extreme or singular (eg person who consumes 5 liters of water a day). * presence of urinary fistula. * men. men will be excluded to avoid the potential influence of prostate problems, the main causes of the symptoms described. * urinary tract infection, or relapses: 5 or more infections in the last 12 months. * participants with bladder stones. * hematuria during the trial period. * pregnancy or plans for it during the study. * the patient has had a hysterectomy. * pathology of the central or peripheral nervous system. * diabetes without controlled and guaranteed medical treatment its stabilization. * diabetes that affects the peripheral nerves. * treated with anticoagulant. * current use of anticholinergics and beta adrenergic use in the last 4 weeks. * currently treated with botox injections for the bladder or in the last year. * current treatment with interstim or interstim device currently implanted. * obstruction of the bladder outlet. * urinary retention. * painful bladder syndrome / interstitial cystitis. * treatment with more than two antidepressants and / or multiple benzodiazepines, as well as anti-epileptics.

Keywords: physical therapy modality electric stimulation therapy urologic diseases pelvic floor disorders
critically ill patient's capacity

Conditions: Decision Making; Critical Illness

Summary: how to determine the decision-making capacity of critically-ill patients remain unclear. the investigator study the differences between standardised evaluation and subjective medical evaluation.

after written information and consent, an independent, specially trained investigator interviews patients with a standardised test. after written information and consent, an independent, specially trained investigator interviews residents, doctors and nurses in charge of the patient and ask them how they rates patients capacity.

Eligibility criteria:
inclusion criteria: * caregivers : doctors, hospital interns, nurses state of both sexes, aged 18 years or more working in intensive care, members of a social security system engaged in a clinic on the day of the assessment * patients : patients of both sexes, aged 18 years or more hospitalized in intensive care, members of a social security system exclusion criteria: -

Keywords: intensive care units judgment disability evaluation autonomy
morphotek investigation in colorectal cancer: research of morab-004 (micro)

Conditions: Metastatic Colorectal Cancer; Colorectal Cancer

Summary: the purpose of this study is to evaluate whether therapy with morab-004 is effective and safe in the treatment of metastatic, colorectal cancer.

tumor endothelial marker-1 also referred to as tem-1 is expressed in the supportive tissue, as well as, on the cells within the tumor. tem-1, which is a cell surface glycoprotein, and is expressed in the stromal compartment (cells) of nearly all human tumors. in preclinical studies, it has been shown that tem-1 plays a key role in tumor growth and the vascularization of tumors. there is evidence suggesting an association between the level of tem-1, 7, 7r, 8 in relation to lymph node involvement and disease progression. morab-004 is a humanized immunoglobulin g (igg1/κ) antibody directed against endosialin/tem-1. nonclinical pharmacological studies showed that morab-004 has the ability to block specific tem-1 receptor-ligand interactions. immunohistochemistry studies of human tumor biopsy samples demonstrate tem-1 expression and morab-004 binding to tumor stromal cells, in particular mural cell compartment of neovessels and cancer-associated fibroblasts. all of which suggests a potential effective treatment. researchers hypothesize that an antibody therapy that binds to tem-1 may be efficacious in the treatment of metastatic, colorectal cancer. this clinical study is a proof of concept study to see if an anti-tem-1 agent is safe and effective in the treatment of metastatic, colorectal cancer.

Eligibility criteria:
inclusion criteria: * males and females \>18 years old * diagnosis of metastatic, colorectal cancer * significant medical conditions must be well-controlled and stable for at least 30 days prior to the first treatment infusion * be willing and able to provide written informed consent exclusion criteria: * no prior treatment for metastatic colorectal cancer * other serious systemic diseases (bacterial or fungal) * clinically significant heart disease or an arrhythmia on an ecg within the past 6 months * known allergic reaction to monoclonal antibody therapy

Keywords: mcrc chemorefractory metastatic colorectal cancer
testing tolerance in cow milk protein allergy patients: milk ladder or direct milk administration?

Conditions: Cow Milk Allergy; Tolerance

Summary: majority of children outgrow their allergies, however there are two different methods to re-introduce milk products in the infant diet either direct milk intake in escalating doses or milk ladder, starting with baked milk products instead of pure milk. this study aims to compare rate of tolerance after milk reintroduction among patient with cow milk protein allergy (cmpa) diagnosed by elimination re-challenge test after six months of elimination diet by milk ladder versus direct milk intake.

cmpa is an immunological response to one or more milk proteins. cmpa may be ige mediated or non-ige mediated. it is one of the most frequent causes of food allergies in young children with an estimated prevalence between 1.9% and 4.9% in the first year of life. cmpa has a good prognosis and cow milk is reintroduced in child diet. natural history of cmpa shows heterogeneity and it is closely related to the clinical phenotype by which it was presented. the timing and evaluation of developing tolerance is determined by clinical response to milk introduction. when diagnosis of cmpa is confirmed, fresh pasteurized cow's milk can be used above 12 months of age in oral food challenge procedure, the starting dose should be lower than a dose that can induce a reaction and then increased step wise to 100ml, in children with mild to moderate reactions doses of 1ml, 3ml, 10ml, 30ml, and 100ml may be given at 30 minutes' intervals. the milk ladder is an evidence-based plan to re-introduce milk products gradually and in stages for infants and children with mild to moderate cow's milk allergy, starting with food that contain only small amount of well-cooked milk and progressing towards uncooked dairy products and fresh milk. it's only started once child has been on a milk free diet for at least 6 months and they are completely well with no active eczema or gastro-intestinal symptoms. addition of baked- milk to the diet appears to accelerate the development of unheated-milk tolerance compared to strict avoidance, also its consumption is considered a form of immunotherapy with favorable safety, higher convenience, lower cost and less intensity when compared to oral immunotherapy. it's suggested to enhance the quality of life by removing unnecessary dietary restrictions and change the natural evaluation of milk allergy by promoting the development of tolerance to regular cow's milk.

Eligibility criteria:
inclusion criteria: 1. patients age between 9 months old till 3 years old. 2. patients with symptoms that suggest mild to moderate non ige mediated cow milk allergy 3. patients on strict elimination diet for at least six months duration exclusion criteria: patient with: * chronic gastrointestinal disease (malabsorption, irritable bowel syndrome). * multiple food allergy and/or history of anaphylaxis. * ongoing eczema or severe gastrointestinal symptoms.
dose response amp challenge study with beclometasone dipropionate (bdp)/formoterol pressurised metered dose inhaler (pmdi)

Conditions: Mild Persistent Asthma

Summary: the aim of this exploratory investigation is to evaluate if the forced expiratory volume in the 1st second (fev1) measurements, fractional exhaled nitric oxide (feno) and provocative concentration 20 (pc20) after adenosine monophosphate (amp) bronchial challenge evaluated after administration of a fixed combination of a long-acting beta-2-agonist (laba) and an inhaled corticosteroid (ics) at increasing doses may be suitable to demonstrate a dose response.


Eligibility criteria:
inclusion criteria: 1. male and female patients 18-50 years of age, who have signed an informed consent form. 2. clinical evidence of asthma 3. steroid naïve asthmatic patients 4. fev1 at screening visit is \>70 % of the predicted value and at least 2.0 l. 5. body mass index between 18 and 35. 6. sensitivity to amp at screening visit. 7. feno levels \>25 ppb at the screening visit exclusion criteria: 1. having received an investigational product within 2 months of screening visit. 2. inability to comply with study procedures or with study treatment intake. 3. any significant lung disease which is considered by the investigator to be clinically significant. 4. patients who suffer from chronic obstructive pulmonary disease (copd) 5. previous or current smokers who have a smoking history greater than 5 pack years. 6. patients with any uncontrolled disease that might, in the judgment of the investigator, place the patients at undue risk or potentially compromise the results or interpretation of the study. 7. patients with qtc \>450msec at the screening visit. 8. patients with serum potassium \ 6 meq/l. 9. intolerance/hypersensitivity or any contra-indication to treatment with beta2-agonists and/or inhaled corticosteroids. 10. patients who have a history of alcohol or substance abuse that in the opinion of the investigator may be of clinical significance. 11. patients who have undergone major surgery in the previous 3 months. 12. patients who have had an exacerbation of asthma, requiring treatment with oral steroids during the last month prior to screening visit. 13. patients treated with slow-release corticosteroids 2 months prior to screening visit. 14. patients currently treated with anti-ige antibodies. 15. patients who have had a respiratory tract infection within 4-weeks prior to screening visit. 16. females not willing to use effective contraceptive measures such as oral contraceptive or intra-uterine device (iud). 17. females who are pregnant, lactating or planning to become pregnant
quality of recovery from obstetric anaesthesia - a multicentre study

Conditions: Obstetric Anesthesia Problems; Anesthesia Morbidity; Quality of Life

Summary: quality of recovery is an important outcome measure in anaesthesia, whilst there are validated tools for this in surgery and regional anesthesia there are no fully validated tools for obstetrics anaesthesia. the aim of this study is to use the obstetric quality of recovery (obsqor) score across multiple centres to assess correlation to length of stay and variation for different types of operative and non- operative delivery.

an observational survey based study, for 3 consecutive week days, chosen by the local investigating team during a two-week period across multiple centres. * local investigators will complete the survey with each patient who has received anaesthetic intervention from an anaesthetist, 1 day, around 24hrs after delivery in line with their routine anaesthetic follow up. * at 30 days, a telephone survey will be conducted with each patient to repeat the obsqor survey and ask key questions regarding functional recovery and activities of daily living post delivery. in addition for a small number of sites, elective caesarean delivery patients will have blood taken at the point of anaesthesia and 24 hours post delivery to assess the immune function and any changes which may predict poorer outcome in these women.

Eligibility criteria:
inclusion criteria: * obstetric patients over 18 years old. * intervention occurring after 32/40 gestation. * all mothers receiving anaesthesia or anaesthetic analgesia during their peripartum period. exclusion criteria: * unable to comprehend the questions asked * patient refusal * under 32/40 weeks gestation * cervical cerclage insertion or removal, anaesthesia for external cephalic verison * neonatal death * non- nhs patients
adverse event data collection from the euhass registry on turoctocog alfa pegol

Conditions: Haemophilia A

Summary: this non-interventional study concerns a safety data collection based on adverse event data from a third-party registry (european haemophilia safety surveillance system, euhass) that includes information about adverse events from patients with haemophilia a treated with turoctocog alfa pegol. there is no extra burden to the patients by participating in this registry-based data collection.


Eligibility criteria:
inclusion criteria: * participation in the european haemophilia safety surveillance system (euhass). exclusion criteria: * n/a
healthy.io method comparison & user performance study

Conditions: Urinary Tract Infection; Kidney Failure; Diabetes

Summary: the objectives of the healthy.io method comparison and user performance study are: 1. to evaluate the performance of dip.io device in comparison to the acon u500 mission® u500 urine analyzer. 2. to evaluate the user performance of dip.io device under actual use conditions (home environment) based on a user questionnaire and rating scale.


Eligibility criteria:
inclusion criteria: 1. subject is male or female, 18-80 years of age 2. subjects who are healthy or pregnant; or 3. subjects diagnosed with a disease that normally represents itself with an abnormal concentration of one of the following urine analytes; glucose, bilirubin, ketone (acetoacetic acid), specific gravity, blood, ph, protein, urobilinogen, leukocytes, and nitrite (examples of such diseases include the following): * diabetes type i, type ii, or gestational diabetes (type iii) or, * urinary tract infection (uti) * heart disease * kidney disease * liver disease * pregnant women with preeclampsia, gestational diabetes or uti * any pathological findings which might be identified by the urine test (according to the physician discretion) 4. subject is capable and willing to provide informed consent. 5. subject has facility with both hands. 6. subject is capable and willing to adhere to the study procedures 7. subject is familiar with the use of a smartphone. exclusion criteria: 1. subject has dementia. 2. subject has mental disorders. 3. subject is visually impaired (cannot read the user manual). 4. subject cannot collect urine in receptacle. 5. any other reason that might preclude the subject from the study.
cryoneurolysis outcome on pain experience (cope) in patients with low-back pain

Conditions: Chronic Low-back Pain; Facet Joint Pain; Degeneration Lumbar Spine; Facet Joint Syndrome; Back Pain Lower Back Chronic

Summary: this study will provide information on the effectiveness of cryoneurolysis for patients with facet joint pain syndrome, and help to establish whether cryoneurolysis should be implemented in clinical practice for this patient population.

background: low-back pain, including facet joint pain, accounts for up to 20 percent of all sick leaves in denmark; among these are patients with facet joint pain syndrome. a proposed treatment option is cryoneurolysis. this study aims to investigate the effect of cryoneurolysis in lumbar facet joint pain syndrome methods: a single-center randomized controlled trial (rct) is performed including 120 participants with chronic facet joint pain syndrome, referred to the department of neurosurgery, aarhus university hospital. eligible patients receive a diagnostic anesthetic block, where a reduction of pain intensity \>50 % on a numerical rating scale (nrs) is required to be enrolled. participants are randomized into three groups to undergo either one treatment of cryoneurolysis, radiofrequency ablation or placebo. fluoroscopy and sensory stimulation is used to identify the intended target nerve prior to administrating the above-mentioned treatments. all groups receive physiotherapy for 6 weeks, starting 4 weeks after treatment. the primary outcome is a reduction in low-back pain intensity and an impression of change in pain after intervention (patient global impression of change (pgic)) at 4 weeks follow-up, prior to physiotherapy. secondary outcomes are quality of life (eq-5d, sf-36) and level of function (oswestry disability index), psychological perception of pain (pain catastrophizing scale) and depression status (major depression inventory). data will be assessed at baseline (t0), randomization (t1), day one (t2), 4 weeks (t3), 3 (t4), 6 (t5) and 12 months

Eligibility criteria:
inclusion criteria: * low-back pain from facet joint syndrom (facet joint pain) \> 3 months' duration with or without neuropathic pain component. * low-back pain on numeric rating scale ≥ 4 exclusion criteria: * presence of nerve root or spinal canal compression; signs of inflammatory or erosive processes in the spine verified on magnetic resonance imaging (mri). * neurological deficits i.e. symptoms of nerve root compression; tingling, numbness, weakness/ paresis, and reflex loss in the lower extremities. * major co-morbidity. * anti-thrombotic or anti-platelet treatment which cannot be paused for a week. * active malignancies. * chronic inflammatory disease. * known severe psychiatric disease. patients with mild and well-treated depression and anxiety are not excluded.

Keywords: low-back pain cryoneurolysis on lower-back pain cryoanalgesia cryoneurolysis cryoneuroablation radiofrequency ablation.